3 results
Approved WMORecruiting
The objective is to compare the efficacy and safety of masitinib 12 mg/kg/day to sinutinib 50 mg/day
Approved WMORecruiting
Safety and efficacy objectives:The objective is to compare the safety and efficacy of masitinib at 6 of 7.5 mg/kg/day to imatinib at 400 or 600 mg, in patients with gastro-intestinal stromal tumour in first line medical treatment.
Approved WMOCompleted
Primary:To characterize the dose response of nemiralisib administered in addition to SoC (standard of care) compared with placebo and SoC in participants diagnosed with an acute moderate or severe exacerbation of COPD. Secondary:Dose response and…